TABLE 1.

Biodistribution Data for ¹⁸F-FB-NAPamide in C57BL/6 Mice Bearing Subcutaneously Xenotransplanted B16/F10 Murine Melanoma and Fox Chase Scid Mice Bearing A375M Human Melanoma

18F-FB-NAPamide	B16/F10			A375M
	1 h	1-h block	4 h	1 h	1-h block
Tumor	1.19 ± 0.11	0.61 ± 0.09	0.25 ± 0.05	0.46 ± 0.11	0.33 ± 0.02
Blood	0.65 ± 0.07	0.51 ± 0.15	0.07 ± 0.01	0.38 ± 0.18	0.28 ± 0.06
Muscle	0.21 ± 0.02	0.20 ± 0.02	0.04 ± 0.02	0.22 ± 0.05	0.20 ± 0.01
Skin	0.35 ± 0.04	0.31 ± 0.06	0.09 ± 0.07	0.35 ± 0.12	0.20 ± 0.04
Bone	0.20 ± 0.02	0.18 ± 0.04	0.14 ± 0.13	0.19 ± 0.06	0.13 ± 0.01
Heart	0.28 ± 0.05	0.21 ± 0.05	0.05 ± 0.02	0.22 ± 0.10	0.19 ± 0.02
Liver	0.79 ± 0.25	0.64 ± 0.18	0.13 ± 0.14	0.53 ± 0.20	0.43 ± 0.08
Lung	0.50 ± 0.06	0.54 ± 0.01	0.10 ± 0.04	0.40 ± 0.15	0.54 ± 0.09
Kidney	6.03 ± 1.53	5.52 ± 1.93	0.53 ± 0.38	2.79 ± 1.09	2.13 ± 0.38
Spleen	0.20 ± 0.03	0.16 ± 0.02	0.09 ± 0.09	0.27 ± 0.08	0.41 ± 0.31
Brain	0.05 ± 0.01	0.05 ± 0.02	0.01 ± 0.01	0.03 ± 0.02	0.02 ± 0.00
Intestine	8.07 ± 7.78	20.62 ± 25.94	0.12 ± 0.08	7.57 ± 5.12	0.91 ± 0.30
Stomach	0.34 ± 0.04	1.65 ± 0.95	0.29 ± 0.23	1.59 ± 2.10	0.56 ± 0.56
Pancreas	0.24 ± 0.06	0.18 ± 0.07	0.16 ± 0.18	0.26 ± 0.12	0.40 ± 0.33
Tumor/blood ratio	1.86 ± 0.44	1.23 ± 0.19	3.60 ± 0.37	1.34 ± 0.39	1.24 ± 0.31
Tumor/muscle ratio	5.63 ± 0.34	3.10 ± 0.19	7.46 ± 2.68	2.07 ± 0.08	1.65 ± 0.10

Data are expressed as percentage administered activity (injected dose) per gram of tissue (%ID/g) after intravenous injection of 740 kBq (20 μCi) ¹⁸F-FB-NAPamide at 1, 4, and 1-h block (with coinjection of 200 μg NDP) (n = 3). Significant inhibition of uptake was observed in B16/F10 melanoma (P < 0.05) but was not observed in A375M melanoma (P > 0.05).